FILE PHOTO: Mankind Pharma logo is seen in this illustration taken, May 9, 2023.
| Photo Credit:
Dado Ruvic
Mankind Pharma has acquired Rivotril from Roche for the Indian market, with exclusive rights for domestic manufacture, marketing and distribution of the product, the company said. The acquisition bolsters Mankind’s neurological products portfolio.
Rivotril is the innovator reference brand of clonazepam prescribed for the management of neurological and psychiatric conditions, Mankind said.
The acquisition aligns with Mankind Pharma’s focus on chronic therapies, where it has expanded presence through new launches, in-licensing partnerships and portfolio additions.
Atish Majumdar, Senior President, Sales and Marketing, Mankind Pharma Specialty Business, said in a statement, the acquisition was aligned with the company’s strategic focus to strengthen its presence in chronic and specialty therapies. “Going forward, we see strong opportunities to build on this platform through potential line extensions, addressing the evolving needs of patients and physicians in the CNS (central nervous system) therapy area. Leveraging our large field force and nationwide distribution network, we are well positioned to build the brand and support physicians in delivering better outcomes for patients across India,” he said. The company engages with over five lakh doctors.
Published on March 18, 2026